European Spine Journal

A new clinical study highlights efficiency in spine surgery of NextAR Spine, augmented reality surgical application

Retrieved on: 
Thursday, December 14, 2023
European Spine Journal, PMID, Education, Ille, Clinic, Kim Sa-ryang, Medicine, Neoplasm, Infection, Surgery, Trial of the century, 3D, Learning curve, Spine, Patient, Instrument, Abdominal ultrasonography, Sports medicine, Ecosystem, Trauma, Workflow, Bookbinding, Surveying, Medical device

A new clinical study highlights efficiency in spine surgery of NextAR Spine, augmented reality surgical application

Key Points: 
  • A new clinical study highlights efficiency in spine surgery of NextAR Spine, augmented reality surgical application
    A new clinical study highlights efficiency in spine surgery of NextAR Spine, augmented reality surgical application
    CASTEL SAN PIETRO, 14 December 2023 - Medacta Group SA (“Medacta”, SIX:MOVE), a Swiss company specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgeries, announces the publication of a new study in the European Spine Journal which demonstrates that NextAR Spine seamlessly integrates into the OR workflow, enabling the surgeon to enhance efficiency, accuracy, and versatility in spine surgery.
  • As stated in our recent study, NextAR, the new AR-assisted navigation system, greatly simplifies pedicle screw placement, ensuring effectiveness and accuracy.
  • The study “Evaluating a cutting‑edge augmented reality‑supported navigation system for spinal instrumentation” 1 led by Prof. Dr. med.
  • The NextAR surgical platform is part of Medacta's MySolutions Personalized Ecosystem , a network of advanced digital solutions designed to improve patient outcomes and healthcare efficiency.

Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

Retrieved on: 
Tuesday, May 23, 2023
Aurora, KOL, Software as a service, European Spine Journal, Opioid, Biomarker, ACON, Pain, CO, Philosophy, Patient, Physician, Advocate Aurora Health, Algorithm, Diagnosis, United, International Society, Rare-earth element, Medical imaging

BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dean Karahalios, M.D., Medical Director of Brain & Spine Institute at Advocate Aurora Health Care in Illinois, will advise the company as a key opinion leader (KOL) nationally.

Key Points: 
  • Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S. and the single most expensive diagnosis in the United States.
  • Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
  • Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain.
  • Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain.

Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

Retrieved on: 
Tuesday, May 2, 2023
Software as a service, Surgeon, European Spine Journal, PI, Low back pain, Discography, Biomarker, ACON, Biomedical engineering, National Institutes of Health, Physical examination, Bangladesh Technical Education Board, Comeback, Pain, CO, MRI, MRS, BEST, Johns Hopkins University, Biomedicine, Patient, Physician, Gornet, CLARITY, Algorithm, FACS, Diagnosis, Multi, Johns Hopkins, Trial of the century, Role, Principal, Second Half, Pharmaceutical industry, Medical imaging, MD

BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nicholas Theodore, MD, Director of Neurosurgical Spine Center at Johns Hopkins University, will serve as the Principal Investigator in a post-market, multi-site trial, that will further evaluate the role of Nociscan in the diagnosis and surgical treatment of patients suffering from chronic low back pain.

Key Points: 
  • “Diagnosing the source of chronic low back pain has been an industry conundrum for decades,” said Dr. Theodore.
  • “Moreover, as clinicians, we are challenged by important limitations with alternative diagnostic tools like MRI and discography.
  • Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain.
  • When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.

Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial

Retrieved on: 
Monday, April 24, 2023
ODI, Low back pain, Clinical trial, Ageing, Discography, Spine, Biomarker, ACON, Pain, CO, MRI, Back pain, I Am the Moon, Oswestry Disability Index, MD, Patient, Physician, Standard of care, Division, Algorithm, CDMI, European Spine Journal, Dentistry, Nursing, Medical imaging

BROOMFIELD, CO, April 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan.

Key Points: 
  • The multi-year, single site clinical trial comprised 78 patients who received surgery for DLBP following standard clinical work-up including MRI and provocative discography.
  • Surgical success rates at 2 years illustrates a 22 percentage point improvement (p = 0.07) between the two groups.
  • Matthew Gornet, MD, orthopedic surgeon and lead author, stated, “The two-year surgical outcomes of the clinical trial are significantly clear on the primary (ODI) endpoint.
  • Aclarion is moving forward with additional clinical trials, which collectively will expand on the impressive foundational evidence compiled by Dr. Gornet and team,” said Brent Ness, CEO at Aclarion.

Philips expands rollout of its ClarifEye augmented reality surgical navigation solution to Japan

Retrieved on: 
Thursday, October 13, 2022
The Spine Journal, 3D CT, Observation, Lumbar spinal stenosis, Literature, AEX, Spine, Trauma, Journal, Scientific Reports, Philips, Surgeon, International University, Scoliosis, Population, EOC, AR, NYSE, 3D, World Neurosurgery, Spinal disease, Orthopedic surgery, Department, Skin, Hospital Sant Joan de Déu Barcelona, International University of Health and Welfare, Journal of Orthopaedic Science, Risk, 2D, Bleeding, European Spine Journal, PHG, Augmented reality, ISSN, Technology, Live Phish Volume 18, Pain, Ageing, Spinal stenosis, Review, Hybrid, Patient, Hospital, MD, Doctor of Philosophy, Prevalence, Intra, Medical device, Medical imaging

Philips augmented reality surgical navigation solution - ClarifEye - combines 2D and 3D visualizations at low X-ray dose with 3D AR navigation into one system.

Key Points: 
  • Philips augmented reality surgical navigation solution - ClarifEye - combines 2D and 3D visualizations at low X-ray dose with 3D AR navigation into one system.
  • Compared to existing navigation systems, ClarifEye has no reference frame-related errors, and its wonderful that it achieves real time imaging with pedicle segmentation.
  • [4] Elmi-Terander A at el, Augmented reality navigation with intraoperative 3D imaging vs fluoroscopy-assisted free-hand surgery for spine fixation surgery, a matched-control study, Nature Sci.
  • accuracy results from a multicenter, prospective clinical study using a skin markerbased optical navigation system, European Spine Journal, Sept 2022.

New Procedure at St. Elizabeth Offers Long-Term Relief for Chronic Back Pain

Retrieved on: 
Tuesday, February 8, 2022
Roman Catholic Diocese of Covington, Pain, Diocese, Vertebra, European Spine Journal, Low back pain, FDA, Pain management, Patient, St. Elizabeth Healthcare (Kentucky), Pain scale, Back pain, Health, Chronic pain, Nursing care plan, MD, Medical imaging, Poultry, Dentistry, Cincinnati metropolitan area

EDGEWOOD, Ky., Feb. 8, 2022 /PRNewswire/ -- Patients with lower back pain now have access to an innovative new procedure that offers long-lasting relief for lower back pain.

Key Points: 
  • EDGEWOOD, Ky., Feb. 8, 2022 /PRNewswire/ -- Patients with lower back pain now have access to an innovative new procedure that offers long-lasting relief for lower back pain.
  • This new procedure gives patients who have not experienced treatment success the possibility of long-term relief from pain.
  • "We have a lot of chronic back pain patients who have tried procedures and medications to no avail," says Lance Hoffman, MD, Interventional Pain Management Specialist at St. Elizabeth Healthcare.
  • This one-time procedure can significantly reduce back pain and is a welcome option to many chronic back pain sufferers.